Moracin O |
Catalog No.GC62406
One-Click Copy Product Info
|
Moracin O is a hypoxia-inducible factor (HIF-1) inhibitor isolated from Morus alba Linn., exhibiting significant anti-inflammatory and antioxidant activities.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 123702-97-6
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Moracin O is a hypoxia-inducible factor (HIF-1) inhibitor isolated from Morus alba Linn., exhibiting significant anti-inflammatory and antioxidant activities[1,2]. Moracin O reduces reactive oxygen species (ROS) generation induced by oxygen-glucose deprivation (OGD)[3] and is commonly used in studies of neuroprotection, oxidative stress, and the regulation of related signaling pathways[4,5].
In vitro, treatment of 4T1-NF-κB reporter cells with Moracin O (3, 10, 100nM) for 24h dose-dependently inhibited NF-κB activity. Pretreatment of HaCaT human keratinocytes with Moracin O (10μM) for 1h, followed by co-incubation with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, 20ng/mL) for 24h, significantly attenuated TRAIL-induced cell damage and improved cell viability[6]. Pretreatment of SK-N-SH human neuroblastoma cells with Moracin O (10μM) for 4h, followed by exposure to 30mM glutamate for 4h, significantly inhibited glutamate-induced cell death[7].
In vivo, Institute of Cancer Research (ICR) mice were pretreated with Moracin O (80mg/kg, i.p.) 30min prior to the injection of 0.7% acetic acid to induce a pain model. Moracin O significantly inhibited acetic acid-induced writhing responses, reducing the mean number of writhes from 17 ± 6 in the control group to 0 ± 1, with an inhibition rate of 98%[7].
References:
[1] NAIK R, HARMALKAR D S, XU X, et al. Bioactive benzofuran derivatives: Moracins A-Z in medicinal chemistry[J]. European Journal of Medicinal Chemistry, 2015, 90: 379-393.
[2] DAT N T, JIN X, LEE K, et al. Hypoxia-inducible factor-1 inhibitory benzofurans and chalcone-derived Diels–Alder adducts from Morus species[J]. Journal of Natural Products, 2009, 72(1): 39-43.
[3] LEE H J, LYU D H, KOO U, et al. Inhibitory effect of 2-arylbenzofurans from the Mori Cortex Radicis (Moraceae) on oxygen glucose deprivation (OGD)-induced cell death of SH-SY5Y cells[J]. Archives of Pharmacal Research, 2011, 34(8): 1373-1380.
[4] LEE J H, KO H J, WOO E R, et al. Moracin M inhibits airway inflammation by interrupting the JNK/c-Jun and NF-κB pathways in vitro and in vivo[J]. European Journal of Pharmacology, 2016, 783: 64-72.
[5] ZOOFISHAN Z, KÚSZ N, CSORBA A, et al. Antispasmodic activity of prenylated phenolic compounds from the root bark of Morus nigra[J]. Molecules, 2019, 24(13): 2497.
[6] HARDIANTI B, UMEYAMA L, LI F, et al. Anti-inflammatory compounds moracin O and P from Morus alba Linn. (Sohakuhi) target the NF-κB pathway[J]. Molecular Medicine Reports, 2020, 22(6): 5385-5391.
[7] WANG Y N, LIU M F, HOU W Z, et al. Bioactive benzofuran derivatives from Cortex Mori Radicis, and their neuroprotective and analgesic activities mediated by mGluR1[J]. Molecules, 2017, 22(2): 236.
| Cell experiment [1]: | |
|
Cell lines |
HaCaT cells |
|
Preparation Method |
HaCaT cells were pre-incubated with 10µM of Moracin O for 1h, then co-cultured with 20ng/mL TRAIL for 24h. Cell viability was determined using a WST-1 assay and normalized to the untreated control. |
|
Reaction Conditions |
10μM; 1h |
|
Applications |
Pretreatment with Moracin O significantly reduced TRAIL-induced cell damage and improved cell survival. |
| Animal experiment [2]: | |
|
Animal models |
Male ICR mice |
|
Preparation Method |
ICR mice were pretreated intraperitoneally (i.p.) with the Moracin O (80mg/kg) in a separate set 30 min before acetic acid injection (0.7%). The mice were placed individually into glass beakers and 5min were allowed to elapse. The mice were then observed for a period of 10min and the number of writhes was recorded for each animal. |
|
Dosage form |
80mg/kg; i.p. |
|
Applications |
Pretreatment with Moracin O significantly inhibited acetic acid-induced writhing responses, reducing the average number of writhing responses from 17 ± 6 in the control group to 0 ± 1, with an inhibition rate of 98%. |
|
References: |
|
| Cas No. | 123702-97-6 | SDF | |
| Formula | C19H18O5 | M.Wt | 326.34 |
| Solubility | Storage | Store at -20°C | |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.0643 mL | 15.3214 mL | 30.6429 mL |
| 5 mM | 612.9 μL | 3.0643 mL | 6.1286 mL |
| 10 mM | 306.4 μL | 1.5321 mL | 3.0643 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 6 reference(s) in Google Scholar.)